Kymera Therapeutics, Inc.

Contributing Author

Recent Articles by Kymera Therapeutics, Inc.

12 hours	Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases KYMR GlobeNewswire
12 hours	Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update KYMR GlobeNewswire
May-07	Kymera Therapeutics to Participate in Fireside Chat at the BofA Securities 2025 Health Care Conference KYMR GlobeNewswire